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results are reported over a one-year period after reaching steady-
state level of vaccination. Multiple probabilistic sensitivity analy-
sis was performed to estimate the distribution of the cost
difference between the two vaccines by running 5000 iterations
with @Risk(r) software in Excel(r) (normal distributions for
vaccine efﬁcacy, uniform distributions for HPV typing and costs).
RESULTS: Multiple probabilistic sensitivity analysis showed
an average annual cost difference of $9.3M (CDN) (95% CI:
-$10M, +$43M) in favor of cross-protection over genital warts
protection. Cross-protection provided additional cost saving
with an 86.3% probability. An efﬁcacy for additional cross
protection of around 12% would achieve cost neutrality. The
difference in cost was most sensitive to vaccine efﬁcacy of cross-
protection, the proportion of non-vaccine oncogenic HPV-types
in CIN1, and the unit cost of treating CIN1. CONCLUSION: A
vaccine with additional cross-protection of at least 12% is likely
to offset the costs associated with the protection against genital
warts in the Canadian health care system.
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OBJECTIVE: In Hungary, costs of anti-cancer treatments are
covered by hospitals’ budget, and funds for therapy expenditures
provided from the National Health Fund Administration, based
on DRG accounts. The goal was to investigate the real cost of
treatments, and assess a comparison ofDRGbased remittance and
expenditures of therapies. METHODS: Cost analysis of CRC
chemotherapy-protocols has been conducted from the perspective
of Oncology Departments. Regimens of 5-ﬂuorouracil+/
-leukovorin, irinotecan, cetuximab, bevacizumab and oxali-
platin have been investigated, focusing on cost of medication,
hospitalisation and total expenditure of protocols. RESULTS:
Real expenditures of protocols were assessed. The range of drug
related costs were USD$18.20–3085.80 as expenditures of hospi-
tals. Total expenditures of chemotherapy-regimens have been
assessed and compared to allocation of remittances from the
National Health Fund Administration. The value of remittances
have been found between USD$405.70 and USD$2875.20,
depending on protocols. The gap analysis of drug expenditures
and remittances has resulted in a wide range of USD$-347 to
USD$1611. The ratio of drug related expenditures and total
remittance of hospitals showed diversity from 5% to 107%.
CONCLUSION: The analysis showed that ﬁxed DRG values had
not represented real expenditures of chemotherapies of CRC
treatment. Remittances should have been validated regularly.
Neither priority, nor incentive elements, have been found in
protocols containingmoleculeswith superior efﬁcacy or improved
safety. In general, Oncology Departments are motivated to use
protocols, containing generic compounds with low expenditures
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OBJECTIVE: As new agents become available for the treatment
of diseases, there exists a need to evaluate the cost-effectiveness
of the agents. This study calculates the cost-per life-year saved
and the budget impact of lapatinib, a new dual tyrosine inhibi-
tor as part of the formulary evaluation process at a major ter-
tiary cancer center. METHODS: A decision analytical model
was developed to estimate the incremental cost-effectiveness of
lapatinib for advanced breast cancer. The model estimates the
incremental cost-effectiveness of two strategies: combination
therapy of lapatinib with capecitabine compared to capecitabine
alone. The outcome of interest was time to disease progression,
based on randomized clinical trials (RCTs). Direct medical costs
from the institutional perspective were utilized and were calcu-
lated for a one year time period. One-way and two-way sensi-
tivity analysis on the rate of disease progression for
monotherapy and combination therapy was conducted. In addi-
tion, a budget impact model was also calculated for the insti-
tution. RESULTS: Based on outcome estimates from RCTs and
the application of the institutional costs, the cost-per-life-year
saved for lapatinib for treatment of advanced breast cancer was
$108,300. One-way sensitivity analysis of the combination
response (0–50%) indicated that lapatinib’s cost-effectiveness
ratios ranged from $100,000 to $119,000 per life-year saved.
Two-way sensitivity analysis indicated that the majority of the
time monotherapy was more cost-effective. The lapatinib com-
bination was only considered cost-effective, if the response rate
of the monotherapy never exceeded 14.6%. The budget impact
model, which incorporated both on-label and off-label usage of
lapatinib, estimated that the institution will utilize about 10
million dollars worth of drugs annually, based on acquisition
costs. CONCLUSION: Lapatinib appears to have similar cost-
effectiveness in comparison with other targeted oncology agents.
Post evaluation economic analysis will be conducted to deter-
mine how closely the economic model predicted the utilization
of lipatinib at the institution.
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OBJECTIVE: Patients with chronic lymphocytic leukemia (CLL)
are often treated with prophylactic intravenous immunoglobulin
(IVIG) to reduce risk of infection, although increased survival has
not been demonstrated with use. The objective of this study was
to estimate direct medical costs of IVIG versus no prophylaxis
over 12 months. METHODS: Costs were estimated from the
government (Medicare) perspective when available, or calculated
from the literature in 2007 US dollars. Assuming a regimen of
400mg/kg every four weeks for one year, 12 administrations for
a 70kg patient was calculated using a reimbursement of $30 per
500mgs. Estimated resources costs were $24 per preparation and
$144 per administration. Infections were considered minor, mod-
erate, or severe and both costs and probabilities of infection were
extracted from previous studies. Risk of any infection with IVIG
use was 36% and with no prophylaxis, 56%. Reported infections
per year among patients with 1+ infection was 1.4 with IVIG use
and 2.25 infections with no prophylaxis. RESULTS: Under
the described model, the total cost per year of prophylactic
IVIG = $24,512 per patient. The weighted average cost per infec-
tion was $1688. The average weighted infection cost (AWIC)
of minor infections = $12; moderate, AWIC = $96; and severe,
AWIC = $2256. In comparison, total cost with no prophylaxis
was $4500 per patient year. The weighted average cost of one
infection with no prophylaxis = $2000. The AWIC of minor
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